August 22, 2014 4:38 PM ET

Life Sciences Tools and Services

Company Overview of Quintiles Transnational Corp.

Company Overview

Quintiles Transnational Corp. provides clinical, commercial, consulting, and capital solutions to biopharmaceutical industry. The company’s clinical development services cover trial types, such as phase I/IIa, phase II/III, late phase, medical devices, and emerging biopharmaceutical; trial services, including bioanalytical and ADME laboratory, biostatistics, biosimilars, central laboratory, clinical monitoring, data management, ECG, functional, lifecycle safety, patient and investigator recruitment, medical writing, model-based drug development, regulatory, and site ID and start up; data intelligence services comprising reporting and analytics, data-driven processes, data archival and wareho...

4820 Emperor Boulevard

Durham, NC 27703-8411

United States

Founded in 1990





Key Executives for Quintiles Transnational Corp.

Chief Executive Officer
Age: 55
Age: 54
Executive Chairman and Member of Executive Committee
Age: 70
Chief Executive Officer of AAA Region and President of AAA Region
Age: 65
Chief Executive Officer of Africa
Compensation as of Fiscal Year 2014.

Quintiles Transnational Corp. Key Developments

Quintiles Presents at Clinical Trial Logistics conference 2014, May-21-2014 02:50 PM

Quintiles Presents at Clinical Trial Logistics conference 2014, May-21-2014 02:50 PM. Venue: Marriott Hotel, Regents Park, 128 King Henry's Road, London, NW3 3ST, United Kingdom. Speakers: Vladimir Anisimov, Senior Strategic Biostatistics Director, Innovation.

BioDelivery Sciences International, Inc. Announces Commercialization Agreement with Quintiles to Support the Launch of BUNAVAIL in the US

BioDelivery Sciences International, Inc. announced that it has entered into an agreement with Quintiles to provide a range of services to support the anticipated launch of BUNAVAIL (buprenorphine and naloxone buccal film), BDSI's proposed maintenance treatment for opioid dependence. BUNAVAIL is currently under review at the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) date of June 7, 2014. Assuming BUNAVAIL is approved, BDSI intends to launch BUNAVAIL in the latter part of third quarter 2014. Under terms of the agreement, Quintiles will provide a range of services to support the launch and subsequent commercialization of BUNAVAIL in the U.S., including a field sales force. Under the direction of BDSI, Quintiles will support the recruitment, training and deployment of a competitively sized sales force capable of reaching the physician base treating the majority of patients with buprenorphine for opioid dependence. In the U.S., nearly 5,000 physicians are responsible for approximately 90% of prescriptions for buprenorphine products for the treatment of opioid dependence according to most recent data from Symphony Health Solutions.

Quintiles Transnational Corp. Presents at Bank of America Merrill Lynch Health Care Conference, May-15-2014 10:40 AM

Quintiles Transnational Corp. Presents at Bank of America Merrill Lynch Health Care Conference, May-15-2014 10:40 AM. Venue: Encore at Wynn Las Vegas, 3121 Las Vegas Blvd South, Las Vegas, Nevada, United States. Speakers: Kevin Gordon, Chief Financial Officer.

Similar Private Companies By Industry

Company Name Region
Virgin Instruments Corp. United States
Plexera Bioscience LLC United States
MedCatheters LLC United States
Acoustic Cytometry Systems, Inc. United States
Bruker-Michrom Inc. United States

Recent Private Companies Transactions

November 20, 2013
Biomoda Inc.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Quintiles Transnational Corp., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at